31 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
IBS trials specify IBS-C, IBS-D, or mixed type using Rome criteria. They are not Crohn's or ulcerative colitis studies. Diet, microbiome, neuromodulator, and secretagogue records all appear. We do not prescribe a diet. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (27) · Phase 2 (3) · Phase 2 / Phase 3 (1)
Intervention hubs that overlap this snapshot: Ketamine
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
NCT02421705 · Official ClinicalTrials.gov record · KU Leuven
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).
NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic
This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
NCT05519683 · Official ClinicalTrials.gov record · University of Michigan
This study wants to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (dummy treatment (placebo)) VR therapy.
NCT05796388 · Official ClinicalTrials.gov record · Mayo Clinic
Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans.
NCT05972291 · Official ClinicalTrials.gov record · VA Office of Research and Development
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease.
NCT05972317 · Official ClinicalTrials.gov record · Weizmann Institute of Science
In the planned how well it works study, a prospective randomly assigned controlled trial will be conducted to investigate the extent to which a multimodal stress reduction and lifestyle modification program can be reflected in patients with irritable bowel syndrome (IBS) within the framework of a clinical study. For this purpose, 118 patients with IBS will be enrolled in a clinical study.
NCT06145022 · Official ClinicalTrials.gov record · Universität Duisburg-Essen
Participants with IBS are skin patch tested (no needles) to 80 different foods and food additives, compounded for patch testing, in search of food allergies. The testing requires 3 office visits within a 4 or 5 day period.
NCT06288672 · Official ClinicalTrials.gov record · IBS-80, LLC
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.
NCT06413004 · Official ClinicalTrials.gov record · Magnus Simrén
The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms.
NCT06668922 · Official ClinicalTrials.gov record · University of California, Los Angeles
To explore the how well it works of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).
NCT06788444 · Official ClinicalTrials.gov record · Beijing Tiantan Hospital
Irritable Bowel Syndrome (IBS), characterized by the Rome IV criteria, is a functional bowel disorder combining abdominal pain with changes in bowel habits and/or stool consistency. This condition is common, affecting 5% to 10% of the population in developed countries.
NCT06801184 · Official ClinicalTrials.gov record · Hospices Civils de Lyon
The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation.
NCT06810518 · Official ClinicalTrials.gov record · American Laboratory Products Company
This study wants to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome (IBS), entitled "WISH," compared to an educational control intervention.
NCT06866106 · Official ClinicalTrials.gov record · Massachusetts General Hospital
Fibromyalgia (FM) is a chronic disorder marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. Patients often experience hyperalgesia, allodynia, and muscle weakness.
NCT06923800 · Official ClinicalTrials.gov record · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Brief Summary : The goal of this clinical trial is to investigate the effects of differing FODMAP diets on gut microbiota, gut barrier function, symptom severity, quality of life, and psychological status in FGID patients. The main question it aims to answer is : How does diets with differing FODMAP content affect the gut microbiota, gut barrier function, symptom severity, psychological status and quality of life in patients with FGID ?
NCT07000227 · Official ClinicalTrials.gov record · Universiti Kebangsaan Malaysia Medical Centre
This clinical study aims to see if a specific combination of probiotics-Lactobacillus rhamnosus GG and Lactobacillus plantarum 299V-can help children and adolescents with Irritable Bowel Syndrome (IBS). IBS is a common digestive condition in children, causing abdominal pain, bloating, and changes in bowel habits (either diarrhoea, constipation, or alternating between the two).
NCT07125625 · Official ClinicalTrials.gov record · University of Bari
Chronic abdominal pain is common among children, and the majority of cases are attributed to functional abdominal pain disorders. One approach to treating these disorders is by using psychological therapies.
NCT07222943 · Official ClinicalTrials.gov record · Baylor College of Medicine
This study is designed to measure the how well it works and safety of camlipixant in adults with IBS-D and IBS-M. After the first part, some you would be randomly chosen again to either get a higher dose or stop the drug.
NCT07519395 · Official ClinicalTrials.gov record · GlaxoSmithKline
This study wants to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and how well it works in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with dummy treatment (placebo).
NCT07545759 · Official ClinicalTrials.gov record · Eli Lilly and Company
This study wants to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and how well it works in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with dummy treatment (placebo).
NCT07545772 · Official ClinicalTrials.gov record · Eli Lilly and Company
To explore the how well it works of pregabalin for patients with irritable bowel syndrome (IBS).
NCT07635394 · Official ClinicalTrials.gov record · Beijing Tiantan Hospital
Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.
NCT07655375 · Official ClinicalTrials.gov record · Guy Boeckxstaens
Irritable Bowel Syndrom (IBS) affects up to five percent of Canadians and has proven difficult to treat. Our research will explore how a type of dietary carbohydrate, called FODMAPS, contributes to chronic abdominal pain in irritable bowel syndrome (IBS).
NCT07688044 · Official ClinicalTrials.gov record · David Reed
Background: Irritable Bowel Syndrome (IBS) affects approximately 4.1% of the global population and imposes a significant personal and healthcare burden. Recent evidence highlights the role of low-grade inflammation, impaired intestinal permeability and gut microbiota dysbiosis in the pathophysiology of non-constipated IBS (IBS with predominate diarrhea; IBS-D and mixed type IBS; IBS-M).
NCT07707635 · Official ClinicalTrials.gov record · Ariel University
The investigators will conduct a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to investigate the effects of Kimchi powder supplementation on gut health in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) for 8 weeks.
NCT07749092 · Official ClinicalTrials.gov record · Pusan National University Yangsan Hospital
Hypothesizing an intestinal barrier impairment as a common pathophysiological substrate of both Non Celiac Wheat Sensitivity (NCWS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD), in a retrospective cohort study (data not yet published), demographic, clinical, laboratory and histology data of NCWS patients at the time of diagnosis, were analyzed and compared to control subjects with Irritable Bowel Syndrome/Functional Dyspepsia (IBS/FD) and freshly diagnosed Celiac Disease (CeD). NCWS diagnosis was performed by a neither you nor the study doctors know who gets the real treatment compared with a dummy treatment wheat challenge.
NCT07750535 · Official ClinicalTrials.gov record · University of Palermo
This cross-sectional, watch-and-measure (no experimental treatment required), controlled comparative study aims to investigate the relationship between interoception and postural control in individuals with constipation-predominant irritable bowel syndrome (IBS-C) and to compare the findings with those of healthy individuals. Interoception will be assessed using the Multidimensional Assessment of Interoceptive Awareness-2 (MAIA-2), postural characteristics will be evaluated using the Corbin Posture Analysis, and stool type in the IBS-C group will be assessed using the Bristol Stool Scale.
NCT07870915 · Official ClinicalTrials.gov record · Saglik Bilimleri Universitesi
This study was designed to determine whether vitamin D supplementation improved symptoms in children with irritable bowel syndrome, a condition associated with repeated abdominal pain and changes in bowel habits. It was hypothesized that vitamin D supplementation would reduce symptom severity and increase blood vitamin D levels compared with dummy treatment (placebo).
NCT07914478 · Official ClinicalTrials.gov record · Aziz Bhatti Shaheed Teaching Hospital
The goal of this clinical trial is to learn whether a probiotic supplement can improve symptoms and quality of life in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea (FD). These conditions can cause frequent loose stools, abdominal discomfort, and a lower quality of life.
NCT07916688 · Official ClinicalTrials.gov record · Szeged University
To describe the prevalence of rosacea in a population of patients with IBS followed at a tertiary-level university medical center.
NCT07922668 · Official ClinicalTrials.gov record · IRCCS Azienda Ospedaliero-Universitaria di Bologna
This hub lists 31 recruiting IBS studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “irritable bowel syndrome” at https://clinicaltrials.gov/search?cond=irritable%20bowel%20syndrome.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Ghent, Belgium; Mexico City, Mexico; Scarborough, Canada; Madrid, Spain; Anaheim, California. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Biologics, JAK inhibitors, and tapering studies for people already on treatment.
B-cell and interferon-pathway drugs for SLE and lupus nephritis.
Injectable biologics, oral TYK2 drugs, and combination skin studies.
Gut-targeted biologics, oral drugs, and diet studies.
Gut-targeted biologics, oral small molecules, and combination induction studies.
Knee and hip pain studies, injections, devices, and exercise programs.